Table 2. Efficacy of Treatment in the ED-SCLC patients (n = 141).
| Group 1 | Group 2 | Group 3 | Group 4 | |
|---|---|---|---|---|
| (n = 31) | (n = 18) | (n = 15) | (n = 77) | |
| Regimen of initial chemotherapy, n (%) | ||||
| CDDP + CPT | 3 (9.7) | 1 (5.6) | 3 (20.0) | 8 (10.4) |
| CDDP + ETP | 0 (0) | 2 (11.1) | 0 (0) | 4 (5.2) |
| CBDCA + CPT | 1 (3.2) | 1 (5.6) | 0 (0) | 0 (0) |
| CBDCA + ETP | 12 (38.7) | 3 (16.7) | 3 (20.0) | 19 (24.7) |
| AMR | 11 (35.5) | 8 (44.4) | 7 (46.7) | 36 (46.8) |
| CPT + AMR | 3 (9.7) | 1 (5.6) | 2 (13.3) | 4 (5.2) |
| Others* | 1 (3.2) | 2 (11.1) | 0 (0) | 6 (7.8) |
| Number of regimen administered, n (%) | ||||
| 1 | 6 (19.4) | 8 (44.4) | 6 (40.0) | 42 (54.5) |
| 2 | 12 (38.7) | 6 (33.3) | 7 (46.7) | 23 (29.9) |
| ≥3 | 13 (41.9) | 4 (22.3) | 2 (13.3) | 12 (15.6) |
| Response to initial chemotherapy, n (%) | ||||
| Partial response | 24 (77.4) | 10 (55.6) | 8 (53.3) | 49 (63.6) |
| Stable disease | 4 (12.9) | 4 (22.2) | 4 (26.7) | 10 (13.0) |
| Progressive disease | 1 (3.2) | 1 (5.6) | 3 (20.0) | 10 (13.0) |
| Not evaluated | 2 (6.5) | 3 (16.7) | 0 (0) | 8 (10.4) |
| Thoracic radiotherapy, n (%) | ||||
| Yes | 6 (19.4) | 1 (5.6) | 3 (16.7) | 7 (9.1) |
| No | 25 (80.6) | 17 (94.4) | 12 (83.3) | 70 (90.9) |
Note: CDDP, cisplatin; CPT, irinotecan; ETP, etoposide; CBDCA, carboplatin; AMR, amrubicin